13.01.2019 22:02:00

Cancer Patient Report Released from Wamberg Genomic Advisors

LA JOLLA, Calif., Jan. 13, 2019 /PRNewswire/ -- The Wamberg Genomic Advisors Cancer Patient Report was released today providing perceptions and insights from U.S. cancer patients regarding their disease management.  To access the full report, go to

The report is based on findings from 204 American cancer patients and their non-professional family/friend advocates.  It indicates that while many cancer patients believe they are getting excellent care and support, all people diagnosed with cancer do not have fast access to the most effective treatments, including professional support and guidance from diagnosis through treatment. The results of the survey are the perceptions of patients and their lay advocates and not results from clinicians.

Top-line survey results report cancer patients' perceptions regarding comprehensive cancer care in three areas:

  • Finding a treatment/solution (diagnosis): Almost half (47 percent) of individuals dealing directly with cancer said there was "no knowledgeable advocate to help" in finding an effective treatment/solution for cancer.
  • Disease management: Respondents wished there was more personalized support in managing the disease with 35 percent wishing another cancer expert was there as an advocate, and 36 percent wanting better support in understanding long-term side effects of the treatment.
  • Support after surgery/chemotherapy/ radiation: Seventy percent (70 percent) of the respondents were cases that required surgery and 47 percent underwent radiation and/or chemotherapy treatments.
  • According to Dr. Philip Smalley, chief medical director of Wamberg Genomic Advisors, "Being diagnosed with cancer is very stressful on the patient and their family. Navigating through the healthcare system, seeing multiple doctors and getting various scans and other tests can be very challenging for the patient and their family to manage. More access to knowledgeable patient advocates is very helpful during these difficult times. Although this is an area that needs more research, some preliminary studies and publications have suggested patients who have access to Cancer Support Services have less time delay starting treatment, fewer hospital readmissions, and overall improved patient satisfaction."

    The survey underscores the challenges that patients and their families face navigating the U.S. complex health-care system from diagnosis to finding a treatment. To access the full report, go to  

    About Wamberg Genomic Advisors
    Wamberg Genomic Advisors is the first company dedicated to making genomic-based programs and services, not typically covered by health insurance, available at prices everyone can afford. Advanced DNA testing can provide insights to individuals and health-care providers for better-informed decisions about overall health, patient-care paths, and the quality and longevity of life. Wamberg Genomic Advisors delivers genomic products and services to employers and their employees via their trusted benefit brokers, and to policyholders of life insurance companies through qualified agents. To discover more about Wamberg Genomic Advisors and the future of genomics, visit  and .

    Cision View original content:

    SOURCE Wamberg Genomic Advisors

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!